Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients (Q28290930)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

14

Paul P Tak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Rogier M Thurlings

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Marie Boumans

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Janneke Tekstra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Joel A van Roon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Koen Vos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Daisy Marie van Westing

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Carina Bos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Kyriakos A Kirou

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Danielle M Gerlag

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Mary K Crow

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Johannes W Bijlsma

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Cornelis L Verweij

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

1 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

published in

Arthritis and Rheumatism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

3607-3614

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

Type I IFNs and their role in the development of autoimmune diseases

10 February 2020

cites work

1 reference

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

21 January 2018

1 reference

Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers.

21 January 2018

1 reference

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

21 January 2018

1 reference

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

Peripheral blood gene expression profiling in Sjögren's syndrome

21 January 2018

1 reference

Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy

21 January 2018

1 reference

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.

21 January 2018

1 reference

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies

21 January 2018

1 reference

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

21 January 2018

1 reference

Interferons as pathogenic effectors in autoimmunity

21 January 2018

1 reference

Recent advances in the genetics of rheumatoid arthritis

21 January 2018

1 reference

Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis

21 January 2018

1 reference

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

21 January 2018

1 reference

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

21 January 2018

1 reference

Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus.

21 January 2018

1 reference

Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.

21 January 2018

1 reference

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

21 January 2018

1 reference

IFN-beta in rheumatoid arthritis

21 January 2018

1 reference

Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block.

21 January 2018

1 reference

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

21 January 2018

1 reference

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

21 January 2018

1 reference

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort

21 January 2018

1 reference

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.

21 January 2018

1 reference

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

21 January 2018

1 reference

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

21 January 2018

1 reference

Rituximab-induced changes in hematolymphoid tissues found at autopsy

21 January 2018

1 reference

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

21 January 2018

1 reference

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

21 January 2018

1 reference

Rituximab treatment in rheumatoid arthritis: how does it work?

21 January 2018

1 reference

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

21 January 2018

1 reference

“Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.27702

2 references

Consolidated OpenCitations Corpus – April 2017

39313

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20722020%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

39313

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

39313